Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir’s C-suite

Lonnel Coats

Lexicon Pharmaceuticals CEO Lonnel Coats will retire July 7, 10 years to the day after accepting the job. Lexicon overcame numerous regulatory obstacles with its SGLT1/2 inhibitor sotagliflozin to earn an FDA approval for heart disease on May 26, 2023, and the treatment is now marketed as Inpefa. Lexicon is giving it another go with the drug in type 1 diabetes following an FDA rejection in this indication; the biotech’s attempts to reverse the CRL also fell short. Sanofi backed out of its alliance with Lexicon after the FDA verdict on sotagliflozin.

“I am truly blessed to have had the opportunity to spend the last decade leading this remarkable company,” Coats said in a statement, adding, “Lexicon has never been stronger.”

Coats also had an 18-year…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks